Oral cromolyn in five patients with ME/CFS and mast cell activation
Rowe PC et al. · 2026 · Cureus
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Selected retrospective case series. The report describes continuous oral use at 1,600–2,400 mg/day in those cases.
Dose, route and schedule
Selected retrospective case series. The report describes continuous oral use at 1,600–2,400 mg/day in those cases.
Protocol source ↗ · Original source
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Mast-cell symptoms | The authors describe improved mast-cell symptoms in all five selected cases. |
The endpoint was mast-cell symptom control in selected patients. The series cannot estimate treatment efficacy or safety for general ME/CFS.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The endpoint was mast-cell symptom control in selected patients. The series cannot estimate treatment efficacy or safety for general ME/CFS.
Source access
Selected retrospective case series. The report describes continuous oral use at 1,600–2,400 mg/day in those cases.
Source reviewed 2026-11-12.
Citation and original source
Original source: Rowe PC et al.. Oral cromolyn in five patients with ME/CFS and mast cell activation Cureus 2026.
Molekul research summary: https://molekul.io/research/cromolyn-mecfs-mcas-2026. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry